NONMEM Users Network Archive

Hosted by Cognigen

Re: Describing Omega that includes both BSV and IOV

From: Paolo Denti <paolo.denti>
Date: Fri, 4 Sep 2015 07:35:40 +0000

Dear SoJeong Yi,
Hyeong-Seok Lim is right, and indeed that ETA in your model is probably accounting for both BOV and BSV.

On the other hand, if your best OFV is obtained with BOV alone (as opposed to BSV alone or both BOV+BSV), this is telling you that the BOV differences are more important than the BSV differences.
In my experience, this is very common for absorption, whose large variability is often driven by accidental factors (food intake, pH in the stomach, stomach emptying time, co-medications, moon phase :) ), rather than real differences between the patients.
I would say that in this case modellers simply report in the paper that the OMEGA was BOV, without any need for further explanation.

I hope this reassures you.

On 2015/09/04 04:49, Hyeong-Seok Lim wrote:
Dear SoJeong Yi,

Sometime we cannot estimate the variances for IIV and IOV separately, although we have multiple dosing data within each subject.

At that time, the alternative could be to combine the IIV and IOV to a single random effect parameter, which is the way you have done.

In this case, the random effect parameter can be described as “random effect parameter reflecting both IIV and IOV”, and so on.

Best regards,

Hyeong-Seok Lim MD PhD

Associate Professor
Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan
88, Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Republic of Korea

Tel: +82-2-3010-4613
Fax: +82-2-3010-4623
LinkedIn: <>
Email: <mailto:mdlhs r<mailto:mdlhs


From: owner-nmusers s
Sent: Friday, September 4, 2015 11:13 AM
To: nmusers>
Subject: [NMusers] Describing Omega that includes both BSV and IOV

Dear all,

Currently I’m summarizing the NONMEM estimates of population PK for writing a manuscript.
However, I wonder how to describe the omega which includes both between-subject variability and inter-occasional variability.
The code of ‘variability’ is followed below,

IF(OCC.EQ.3) IOV = ETA(10)
KA = THETA(9) * EXP(IOV) (--> In final model, PK parameter was estimated like this)
; KA = THETA(9) * EXP(ETA(4)+IOV) (--> When I used this code, there were some problems (boundary error, large RSE (>80%), very small estimate of BSV and so on) )
; KA = THETA(9) * EXP(ETA(4)) (--> when I used BSV only, the OFV is quite higher than upper two cases, so I thought that IOV should be considered. )


In this case, the individual eta was re-calculated in one subject according to occasion, isn’t it?
Then, how should I describe this ‘variability’ and estimate of omega in a manuscript?
(i.e., between subject variability containing inter-occasional variability? Or any other appropriate term?)

I will appreciate if someone give any advice. Thanks in advance.

Best regards,
SoJeong Yi
SoJeong Yi, Ph.D
Department of Clinical Pharmacology and Therapeutics,
Seoul National University College of Medicine and Hospital
101 Daehak-ro, Jongno-gu, Seoul 110-744, Korea
Tel: 82-2-740-8291
Fax: 82-2-742-9252
C.P: 82-10-3178-4133
E-mail: <mailto:sjyi> sjyi

Paolo Denti, PhD
Pharmacometrics Group
Division of Clinical Pharmacology
Department of Medicine
University of Cape Town

K45 Old Main Building
Groote Schuur Hospital
Observatory, Cape Town
7925 South Africa
phone: +27 21 404 7719
fax: +27 21 448 1989
email: paolo.denti lto:paolo.denti


This e-mail is subject to the UCT ICT policies and e-mail disclaimer published on our website at or obtainable from +27 21 650 9111. This e-mail is intended only for the person(s) to whom it is addressed. If the e-mail has reached you in error, please notify the author. If you are not the intended recipient of the e-mail you may not use, disclose, copy, redirect or print the content. If this e-mail is not related to the business of UCT it is sent by the sender in the sender's individual capacity.

Received on Fri Sep 04 2015 - 03:35:40 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: